Assembly Biosciences(US:ASMB)2024-11-07 21:14Financial Performance - Revenue from collaborative research was $6.8 million for Q3 2024, compared to $0 for the same period in 2023, attributed to the collaboration with Gilead[4] - Net loss attributable to common stockholders was $9.6 million, or $1.51 per share, for Q3 2024, compared to a net loss of $14.4 million, or $3.29 per share, for Q3 2023[4] - Total operating expenses for Q3 2024 were $17.8 million, compared to $15.0 million for Q3 2023[4] Research and Development - Positive Phase 1a interim data for ABI-5366 showed a favorable safety profile with a half-life of approximately 20 days and well-tolerated exposures of up to 70 days[1] - ABI-5366 Phase 1b trial initiated for recurrent genital herpes, with interim data expected in the first half of 2025[1] - ABI-4334 Phase 1b trial ongoing for chronic HBV, with interim data expected by the end of 2024[1] - ABI-1179 and ABI-6250 candidates are on track to enter the clinic by the end of 2024[4] Financial Position - Cash, cash equivalents, and marketable securities totaled $95.0 million as of September 30, 2024, down from $109.2 million as of June 30, 2024, projected to fund operations into Q1 2026[4] - Total liabilities as of September 30, 2024, were $74.3 million, down from $95.7 million at the end of 2023[4] Expense Trends - Research and development expenses increased to $13.5 million in Q3 2024, up from $10.8 million in Q3 2023, due to more candidates in development[4]